Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin; Arthritis, Rheum...

Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 02/06/1998, Revision: 58, Status: Authorised Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin;Arthritis, Rheumatoid;Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 02/06/1998, Revision: 58, Status: Authorised

Wil je het laatste nieuws in jouw mailbox ontvangen?
Meld je dan aan voor de nieuwsbrief.